Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
2
Neutral
6
Bullish
6
Bearish
34
Neutral
6
Bullish
6
Bearish
32
Neutral
0
Bullish
0
TruAlt Bioenergy Limited is an integrated Indian biofuels company producing first‑generation ethanol, compressed biogas (CBG), extra neutral alcohol, CO2, DDGS and liquid fermented organic manure, while operating a growing biofuel retail network; it is one of India’s largest ethanol producers by installed capacity and holds Oil Marketing Company status enabling downstream retail participation and offtake capture.
For nine months ended December 31, 2025 consolidated total income rose 13.3% to ₹1,187.05 crore and consolidated EBITDA increased ~10% to ₹170.99 crore, while consolidated PBT edged down slightly due to higher finance costs and depreciation tied to recent capex; standalone PAT declined reflecting increased interest and amortisation from the expanded asset base.
The company is actively diversifying beyond ethanol with a staged CBG expansion via JVs with Sumitomo and GAIL, an advanced SAF project anchored by a Honeywell UOP licensing agreement and proposed ₹2,250 crore capex, and a rapid retail rollout that targets tens to hundreds of dispensaries for downstream integration and stable cash flows.
CBG already demonstrates exceptional unit economics: 9M FY26 CBG EBITDA margin expanded to ~63% and PAT margin to ~43%, validating the scalable green‑gas model; co‑product monetisation (DDGS, CO2, LFOM) and dual‑feed ethanol integration are expected to materially uplift blended margins and reduce seasonality.
Key near‑term risks include timing and quantum of policy support for SAF and CBG incentives, dependence on OMC offtake scheduling, and leverage pressure from recent capex with a debt/EBITDA ratio ~4.6 and debt/equity ~0.65, which could constrain free cash flow until projects ramp to steady state.
Agricultural Food & other Products
Other Agricultural Products
3,661 Cr
Low Risk
24.2
28.7
0.8
2.4
541.95
310.70
Sales CAGR
Profit CAGR
ROE
ROCE
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
TruAlt Bioenergy Ltd (TRUALT) is currently trading at 428.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
TruAlt Bioenergy Limited is an integrated Indian biofuels company producing first‑generation ethanol, compressed biogas (CBG), extra neutral alcohol, CO2, DDGS and liquid fermented organic manure, while operating a growing biofuel retail network; it is one of India’s largest ethanol producers by installed capacity and holds Oil Marketing Company status enabling downstream retail participation and offtake capture. For nine months ended December 31, 2025 consolidated total income rose 13.3% to ₹1,187.05 crore and consolidated EBITDA increased ~10% to ₹170.99 crore, while consolidated PBT edged down slightly due to higher finance costs and depreciation tied to recent capex; standalone PAT declined reflecting increased interest and amortisation from the expanded asset base. The company is actively diversifying beyond ethanol with a staged CBG expansion via JVs with Sumitomo and GAIL, an advanced SAF project anchored by a Honeywell UOP licensing agreement and proposed ₹2,250 crore capex, and a rapid retail rollout that targets tens to hundreds of dispensaries for downstream integration and stable cash flows. CBG already demonstrates exceptional unit economics: 9M FY26 CBG EBITDA margin expanded to ~63% and PAT margin to ~43%, validating the scalable green‑gas model; co‑product monetisation (DDGS, CO2, LFOM) and dual‑feed ethanol integration are expected to materially uplift blended margins and reduce seasonality. Key near‑term risks include timing and quantum of policy support for SAF and CBG incentives, dependence on OMC offtake scheduling, and leverage pressure from recent capex with a debt/EBITDA ratio ~4.6 and debt/equity ~0.65, which could constrain free cash flow until projects ramp to steady state.
Over the past 52 weeks, TruAlt Bioenergy Ltd has traded between a low of ₹310.70 and a high of ₹541.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
TruAlt Bioenergy Ltd has a market capitalization of approximately 3,660.78. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
TruAlt Bioenergy Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 24.17 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,660.78 Cr, TruAlt Bioenergy Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
TruAlt Bioenergy Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of TruAlt Bioenergy Ltd is 24.17. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
They approved material related party transactions with Nirani Sugars Limited, authorising an aggregate value of up to ₹2,500 crore for FY2026-27.
One summary reported PAT at ₹59.27 crore versus ₹4.73 crore a year ago, while another results note reported consolidated net profit at ₹5.93 crore versus ₹0.47 crore.
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
426.90 | 3,661 Cr | 24.17 | 2.41 | 0.00 | 6.85 | 9.45 | 4.22 | ||
676.40 | 3,479 Cr | 14.00 | 1.94 | 0.74 | 16.84 | 17.21 | 9.01 | ||
101.65 | 2,036 Cr | 44.37 | 2.50 | 0.00 | 26.31 | 26.34 | 0.00 | ||
79.98 | 1,657 Cr | 21.15 | 2.76 | 0.00 | 12.36 | 12.74 | 6.75 | ||
94.77 | 1,443 Cr | 17.23 | 2.58 | 0.84 | 11.59 | 13.65 | 9.91 | ||
287.95 | 1,432 Cr | 11.44 | 1.89 | 1.04 | 13.69 | 17.68 | 12.04 | ||
160.40 | 1,000 Cr | 23.46 | 1.56 | 0.94 | 6.66 | 8.68 | 3.30 | ||
| Median: 7 Co. | — | 160.40 | 1,657 Cr | 21.15 | 2.41 | 0.74 | 12.36 | 13.65 | 6.75 |
